Gene Therapy Stock $QURE Crashes 49% as FDA Rejects AMT-130 Data; Class Action Looms

uniQure N.V. ($QURE) faces mounting legal pressure following a catastrophic stock collapse triggered by an unexpected FDA reversal on its flagship gene therapy candidate. On November 3, 2025, the Dutch biotechnology company disclosed that the U.S. Food and Drug Administration no longer believes Phase I/II clinical data for AMT-130 provides adequate support for a Biologics License Application (BLA) submission—a dramatic departure from the company's previous assertions about the drug's regulatory pathway. The revelation sent $QURE stock plummeting 49% in a single trading session, from $67.69 to $34.29, erasing billions in shareholder value and triggering securities litigation against the company's leadership.

The sharp reversal has prompted a class action lawsuit alleging the company failed to disclose material information about AMT-130's regulatory standing despite earlier statements suggesting a high probability of FDA accelerated approval. Affected investors with losses exceeding $100,000 must file lead plaintiff applications by April 13, 2026, marking a critical deadline in what could become a major shareholder litigation case.

The Disclosure That Changed Everything

The core issue centers on a fundamental disconnect between uniQure's public representations and regulatory reality. Prior to November 3, the company had positioned AMT-130—a gene therapy treatment for Huntington's disease—as a candidate poised for accelerated approval based on promising Phase I/II data. This regulatory pathway offers expedited review timelines and reduced data requirements compared to standard BLA submissions, a crucial advantage in competitive biotechnology markets where first-mover advantages can be worth hundreds of millions of dollars.

The FDA's sudden repositioning suggests that:

• Early-stage clinical data fell short of regulatory expectations for advanced approval pathways
• The agency identified potential safety or efficacy concerns requiring additional evidence
• The company's previous guidance about regulatory probability may have been overly optimistic or based on outdated FDA feedback
• Material discussions with regulators were either not disclosed or disclosed with misleading framing

This type of regulatory setback is particularly damaging in gene therapy, where development costs are extraordinarily high, clinical timelines extend years, and each regulatory decision point carries existential weight for smaller biotech firms.

Market Context: Gene Therapy Under Scrutiny

The $QURE collapse occurs against a backdrop of intensifying FDA oversight of gene therapy programs. The biotech sector has faced increased regulatory skepticism following safety concerns and manufacturing challenges that plagued earlier gene therapy candidates. uniQure itself has a complicated history with the FDA, having faced previous setbacks and manufacturing compliance issues.

The class action lawsuit reflects broader investor concerns about:

• Corporate disclosure standards: Whether biotech companies adequately communicate changing regulatory dynamics to shareholders in real-time
• Management credibility: How leadership characterizes uncertain approval pathways and probability assessments
• Risk transparency: Whether material regulatory discussions are properly reflected in forward-looking statements and risk disclosures

In the competitive gene therapy landscape, where companies like Bluebird Bio ($BLUE), REGENXBIO ($RGNX), and others are advancing similar programs, regulatory clarity is paramount. A 49% single-day stock crash suggests the market viewed the FDA's position reversal as not just disappointing news, but as evidence of inadequate prior disclosure.

Investor Implications and Shareholder Recovery Path

For investors holding $QURE shares through the November 3 collapse, the implications are severe:

• Portfolio impact: A 49% daily loss represents catastrophic value destruction, particularly for retail investors who may have accumulated positions based on regulatory optimism
• Lead plaintiff status: Large-loss shareholders meeting the $100,000 threshold have financial incentive to serve as lead plaintiffs, potentially recovering a portion of losses through settlement or judgment
• Litigation timeline: Class action resolution typically requires 2-5 years, meaning any recovery remains years away and uncertain
• Company viability: With AMT-130's regulatory path now uncertain, uniQure's pipeline depth and financial runway become critical questions for remaining shareholders

The lead plaintiff deadline of April 13, 2026 creates urgency for affected investors to document losses and engage with litigation counsel. Institutional investors and those holding through index funds may participate in the class without active involvement.

What Comes Next

The legal proceeding will likely focus on when uniQure management knew or should have known about FDA skepticism regarding AMT-130's regulatory adequacy. Defense counsel will argue that biotechnology inherently involves regulatory uncertainty and that companies cannot guarantee FDA agreement at each discussion stage. Plaintiffs' counsel will examine:

• Internal communications and FDA meeting notes
• Timing of regulatory feedback relative to public statements
• SEC filings and conference call language regarding approval probability
• Whether executives made individual securities transactions suggesting inside knowledge of problems

Beyond litigation, uniQure faces existential questions about its clinical and financial future. The company must now determine whether additional clinical data could satisfy FDA concerns, whether alternative regulatory pathways exist, or whether to redirect resources to other programs in its portfolio.

For the broader biotech investment community, the $QURE case reinforces the importance of scrutinizing regulatory probability claims and FDA feedback characterization. Gene therapy companies operating with limited financial runway face particular pressure to present optimistic regulatory scenarios, making independent evaluation of clinical data and regulatory dynamics essential for sophisticated investors.

The April 2026 lead plaintiff deadline marks the formal beginning of what could become a significant securities litigation outcome, serving as a cautionary tale about disclosure rigor in biotechnology and the tangible consequences of regulatory miscommunication for shareholder value.